Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (24)

« Back to Publications

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial

Cappuccini F. et al, (2020), Journal for ImmunoTherapy of Cancer, 8, e000928 - e000928

5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy

Cappuccini F. et al, (2017), Oncotarget, 8, 47474 - 47489

Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer

Cappuccini F. et al, (2016), Cancer Immunology, Immunotherapy, 65, 701 - 713

The Human Vaccines Project: A roadmap for cancer vaccine development

Romero P. et al, (2016), Science Translational Medicine, 8

Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses

Harrop R. et al, (2008), Cancer Immunology, Immunotherapy, 57, 977 - 986

Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses

Harrop R. et al, (2007), Clinical Cancer Research, 13, 4487 - 4494

Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated

Harrop R. et al, (2006), Cancer Immunology, Immunotherapy, 55, 1081 - 1090

Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial

Harrop R. et al, (2006), Clinical Cancer Research, 12, 3416 - 3424

Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial

Harrop R. et al, (2006), Clinical Cancer Research, 12, 3416 - 3424

Identification of a major histocompatibility complex class I‐restricted T‐cell epitope in the tumour‐associated antigen, 5T4

Redchenko I. et al, (2006), Immunology, 118, 50 - 57

Identification and functional validation of MHC Class I epitopes in the tumour-associated antigen 5T4

Shingler WH. et al, (2005), IMMUNOLOGY, 116, 34 - 34

Phase II studies of MVA expressing the tumour antigen 5T4 given with 5-FU based chemotherapies: safety, immunogenicity and clinical responses

Drury N. et al, (2005), IMMUNOLOGY, 116, 34 - 34

Vaccination Against the Tumour Associated Antigen 5T4 Induces Immune Responses in Advanced Colorectal Cancer Patients: Results Phase I/II Clinical Trial with Recombinant Modified Vaccinia Virus Ankara(TroVax)

Hawkins R. et al, (2004), Journal of Immunotherapy, 27, S54 - S54

Monitoring of Human Immunological Responses to Vaccinia Virus

Harrop R. et al, (2004), 243 - 265

Pre-existing immunity to vaccinia virus does not affect efficacy of a recombinant MVX vaccine: Poxvirus cross-reactivity

Redchenko I. et al, (2004), IMMUNOLOGY 2004: IMMUNODEFICIENCY, INFECTIOUS DISEASES, IMMUNOMODULATION, AND VACCINES, 459 - 464

Load More